Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease

In Gaucher disease (GD), genetic deficiency of acid β-glucosidase leads to accumulation of its substrate glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph). Lipid-laden cells, most prominently seen as macrophages engorged with GlcCer and GlcSph-laden lysosomes, trigger chronic metabolic infl...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Nathaniel Kleytman, Jiapeng Ruan, Audrey Ruan, Bailin Zhang, Vagishwari Murugesan, Haiqun Lin, Lilu Guo, Katherine Klinger, Pramod K. Mistry
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Elsevier 2021-12-01
Цуврал:	Molecular Genetics and Metabolism Reports
Нөхцлүүд:	Gaucher disease Substrate reduction therapy Glucosylsphingosphingosine Eliglustat Splenomegaly
Онлайн хандалт:	http://www.sciencedirect.com/science/article/pii/S2214426921000926
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!